阻断乙肝和丁肝病毒进入肝细胞作为治疗慢性感染的新型免疫疗法
慢性HBV/HDV感染可致癌,现有核苷(酸)类似物(NAs)治疗需终身用药且不能消除癌症风险。该研究设计了一种由针对HDAg的健康初始T细胞驱动的免疫疗法,以绕过HBV特异性T细胞缺陷,诱导PreS1特异性T细胞和阻断HBV进入的PreS1抗体。最佳疫苗候选可在体外诱导体液和细胞免疫,过继转移PreS1抗体可在人源化小鼠中预防或调节后续HBV感染。
要点
- 针对HDAg的初始健康T细胞可绕过慢性乙肝中HBV特异性T细胞功能障碍。
- 最佳疫苗候选诱导PreS1抗体和HBV/HDV特异性T细胞。
- PreS1抗体过继转移可在人源化小鼠中预防或调节HBV感染。
核心结论
- 靶向病毒进入的新型免疫疗法可补充NAs和抑制病毒成熟疗法,用于慢性HBV/HDV感染。
研究设计与样本
- 在细胞培养中评估鼠和兔PreS1特异性抗体对HBV的中和作用,并在人肝细胞重建小鼠中测试兔抗PreS1抗体对HBV的中和。
主要发现
- 最佳疫苗候选诱导针对PreS1和HDAg的T细胞,以及体外阻断HBV进入的PreS1抗体。
- PreS1抗体过继转移可在人源化小鼠中预防或调节后续攻毒后的HBV感染。
临床怎么用
- 该策略靶向病毒进入,旨在补充NAs和即将用于抑制病毒成熟的疗法。
- PreS1抗体过继转移可能用于预防或调节HBV感染。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic hepatitis B and D virus (HBV/HDV) infections can cause cancer. Current HBV therapy using nucleoside analogues (NAs) is life-long and reduces but does not eliminate the risk of cancer. A hallmark of chronic hepatitis B is a dysfunctional HBV-specific T-cell response. We therefore designed an immunotherapy driven by naive healthy T cells specific for the HDV antigen (HDAg) to bypass the need for HBV-specific T cells in order to prime PreS1-specific T cells and PreS1 antibodies blocking HBV entry. METHODS: Ten combinations of PreS1 and/or HDAg sequences were evaluated for induction of PreS1 antibodies and HBV- and HDV-specific T cells in vitro and in vivo. Neutralization of HBV by PreS1-specific murine and rabbit antibodies was evaluated in cell culture, and rabbit anti-PreS1 were tested for neutralization of HBV in mice repopulated with human hepatocytes. RESULTS: The best vaccine candidate induced T cells to PreS1 and HDAg, and PreS1 antibodies blocking HBV entry in vitro. Importantly, adoptive transfer of PreS1 antibodies prevented, or modulated, HBV infection after a subsequent challenge in humanized mice. CONCLUSIONS: We here describe a novel immunotherapy for chronic HBV/HDV that targets viral entry to complement NAs and coming therapies inhibiting viral maturation.
引用
- Maravelia P, Frelin L, Ni Y, et al. Blocking Entry of Hepatitis B and D Viruses to Hepatocytes as a Novel Immunotherapy for Treating Chronic Infections. J Infect Dis. 2021. PMID: 31994701. doi:10.1093/infdis/jiaa036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。